In Brief
Integrative whole-genome and -transcriptome sequencing provides a comprehensive view of structural variations that affect major regulators in prostate cancer and would escape detection by exome-based approaches.
INTRODUCTION
Prostate cancer represents a common and clinically heterogeneous disease entity. While over 160,000 American men are diagnosed with prostate cancer each year, <20% of patients will experience progression to the lethal form of the disease, termed metastatic castration-resistant prostate cancer (mCRPC) (Siegel et al., 2018) . A major barrier to studying mCRPC has been the difficulty in obtaining tumor samples, as clinical biopsies of metastatic lesions are not routinely performed. mCRPC has recently been evaluated by targeted or whole-exome sequencing (Armenia et al., 2018; Beltran et al., 2013; Grasso et al., 2012; Robinson et al., 2015; Zehir et al., 2017) . These studies identified alterations in pathways involving androgen signaling, DNA repair, and phosphoinositide 3-kinase (PI3K) signaling, as well as recurrent mutations in genes such as SPOP, FOXA1, and IDH1. However, the exome represents <2% of the genome, and outside of small case series (Gundem et al., 2015; Wedge et al., 2018) , the complete genomic landscape of mCRPC remains largely unexplored.
Genomic structural variants (SVs) include genomic deletions, insertions, tandem duplications, inversion rearrangements, and inter-chromosomal translocations. SVs are prevalent in prostate cancer, with gene fusions involving the E26 transformation-specific (ETS) family of transcription factors identified in 40%-60% of cases (Maher et al., 2009; Tomlins et al., 2005 Tomlins et al., , 2007 . A recent study in localized prostate cancer demonstrated clusters of genomic rearrangements each occurring in 5%-6% of samples (Fraser et al., 2017) . In addition, previous studies have demonstrated that SVs may define subtypes of ovarian, pancreatic, and breast cancers (Nik-Zainal et al., 2016; Patch et al., 2015; Waddell et al., 2015; Wang et al., 2017) . Of note, the majority of SVs involve intergenic or intronic noncoding regions of the genome and are not captured by exome sequencing or transcriptome analysis. A key advantage of whole-genome sequencing (WGS) over exome sequencing is that WGS allows the identification of SVs that alter the activity of key driver genes, tumor suppressors, and regulatory elements.
To comprehensively investigate the genomic drivers of mCRPC, we interrogated the whole genomes and transcriptomes of mCRPC samples from over 100 patients at a mean depth of 109X in tumors, a depth 2-3 times greater than that achieved in previous large WGS studies in cancer. Deep sequencing of a large patient cohort permitted us to discover novel recurrent SVs and define the prevalence of these variations in mCRPC. We discovered previously unidentified recurrent SVs modulating tumor suppressors or oncogenes, identified new rearrangements coupling noncoding genes to known cancer drivers, and uncovered novel global associations between DNA repair alterations and SVs.
RESULTS
A multi-institutional consortium conducted a prospective IRBapproved study (NCT02432001) that obtained and profiled metastatic tumor biopsies from prostate cancer patients with castration-resistant disease (Aggarwal et al., 2016) . Image-guided core biopsies were obtained (Holmes et al., 2017) and fresh-frozen. Tumor tissue was centrally processed and banked. Laser capture microdissection was used to isolate samples enriched for cancer, and sequencing of RNA was performed. Whole-genome DNA sequencing was performed from frozen sections for tumor and from peripheral blood for matched normal samples, obtaining a mean depth of 109X in tumor and 38X in normal samples ( Figure S1 ). Paired end mRNA libraries were sequenced to a median depth of 114 M paired reads. This report includes results from 101 patients, including mCRPC lesions from bone (n = 42), lymph node (n = 40), liver (n = 11), or other soft tissue sites (n = 8) (clinical summary in Table 1 , sample-level features related to sequencing, molecular analysis, and biopsy site in Table S1 ). Of these patients, 64% had received second-generation anti-androgen therapy (abiraterone: 47%, enzalutamide: 37%, both: 20%).
Structural Variations Disrupt Key Driver Genes
The frequency of genomic copy number alterations in our mCRPC tumors was consistent with previous exome sequencing reports (Armenia et al., 2018; Beltran et al., 2013; Grasso et al., 2012; Robinson et al., 2015) (Figures 1A and S2A ). The percent of the genome altered in each sample ranged between 7% and 47% (median 23%; Table S1 ). The median mutation frequency was 4.1 mutations/Mb, slightly lower than the 4.4 mutations/Mb reported previously in mCRPC , but greater than the 0.53 mutations/Mb reported in primary prostate cancer (Fraser et al., 2017) . Approximately 40% of tumors were triploid ( Figure S2B ; Table S1 ). Triploid status was associated with more translocations and mutations overall (p < 0.007, Figures S2C and S2D) .
We systematically identified loci most frequently affected by structural variations by counting SVs within 1 Mb windows genome-wide (SV per window 9.6 ± 5.1; mean ± SD, listed in Table S2 ). The frequency of SVs is plotted in concert with copy number alteration frequencies in Figure 1A . The loci most frequently affected by SV (>3 SD from mean) contained key drivers of prostate cancer, underscoring the importance of structural variation in this disease. This included AR, the transmembrane serine protease 2 (TMPRSS2), and ETS transcription factor (ERG) genes that produce the TMPRSS2/ERG fusion protein, the oncogene MYC, Forkhead Box protein A1 (FOXA1), and phosphatase and tensin homolog (PTEN). This analysis also identified clusters of deletions affecting genes at fragile sites previously identified in more than one cancer type (Bignell et al., 2010; Glover et al., 2017 ).
An integrated analysis of SVs and mRNA expression levels was then used to define cases where SVs were predicted to inactivate tumor suppressors. PTEN was affected by biallelic alterations in 36% of tumors and monoallelic alterations in 26% of tumors ( Figure 1B ). The PTEN sequence or promoter was frequently interrupted by a translocation (7% of cases) or inverted rearrangement (5% of cases, Figure S3A ). SV were essential to assigning biallelic PTEN alteration status in 8% of cases and mono-allelic PTEN alteration status in 5% of cases (Figure 1B, left) . TP53 was affected by biallelic somatic alterations in 46% of tumors and monoallelic alterations in 30% of tumors, with 11% of the biallelic assignments due to SV gene disruption. SVs also contributed to biallelic inactivation of RB1 (12% biallelic, 3% by SV), CDKN1B (7% biallelic, 1% by SV), and CHD1 (7% biallelic, 2% by SV) ( Figure 1B ). There was a significant association between the number of inactivated alleles and mRNA levels of PTEN, TP53, CDKN1B, RB1, and CHD1 ( Figure 1B , right), suggesting monoallelic alterations impacted expression levels of these genes.
Novel Gene Fusions Predicted to Activate Oncogenes
We then determined cases where structural variants were predicted to activate driver genes by integrating SV data, mRNA expression levels, and predicted mRNA fusions. A majority of prostate cancers harbor fusions from the juxtaposition of the 5 0 regulatory region of the androgen-responsive gene TMPRSS2 upstream of ERG (Tomlins et al., 2005) . We observed mutually exclusive fusions activating the ETS family members ERG, ETV1, ETV4, and ETV5 in 59% of our cohort ( Figure 1C ; fusions listed in Table S3 ). In four cases, an ETS family member fused to a gene not previously reported in mCRPC, including ETV1 fusions driven by the solute carrier SLC30A4 and ETV4 fusions driven by transmembrane and coiled-coil domain family 2 (TMCC2), clathrin heavy chain (CLTC), and cell division cycle 6 (CDC6). We also identified novel fusions between coding and non-coding genes, exemplified by SCHLAP1, a lncRNA highly enriched in a subset of aggressive prostate cancers (Prensner et al., 2013) . The PI3K pathway member PIK3CA was expressed at very low levels except for a single sample bearing a translocation that placed the first exon of SCHLAP1 immediately downstream of the PIK3CA 5 0 UTR, resulting in the overexpression of a full-length PIK3CA transcript ( Figure S3B ). In two other cases, ETV1 was translocated to chromosome 14 between FOXA1 and mirrorimage polydactyly 1 (MIPOL1). The lncRNA RP11-356O9.1 (also annotated as AL121790.1) lies in this region. Previously published data showed that in normal tissues, RP11-356O9.1 is expressed exclusively in prostate ( Figure S4 ). In these two cases, the first exon of RP11-356O9.1 was fused to exon 4 or exon 5 of ETV1 ( Figure 1D ). Fusions between ETV1 and this region have been previously reported in the prostate cancer cell line MDA-PCa 2B (Tomlins et al., 2007) and in a single patient sample (Abeshouse et al., 2015) .
Multiple low-frequency gene fusions involving oncogenes, including AXL, BRAF, and MYC, were also noted (Figures 1E and S3B) . A gene fusion joined prostatic acid phosphatase (ACPP) residue 380 (NM_001009) to the transmembrane receptor tyrosine kinase AXL at residue 429 (NM_001699), producing an in-frame transcript. Review of an independent cohort of patients with high risk primary prostate cancer identified a similar ACPP-AXL fusion, demonstrating these fusions are a Figure S3 .
repeated finding ( Figure S3C ). In a case lacking high level MYC DNA copy number amplification, ACPP was fused to MYC within 150 nt of the MYC 5 0 untranslated region, originating within the second and third ACPP exons. Collectively, these novel, low frequency gene fusions could represent therapeutic targets in mCRPC.
Duplications Target AR, MYC, and FOXA1 Genomic duplication events are a mechanism of genome evolution (Ohno, 1970) and are known to alter specific drivers important in cancer, such as FLT3 in acute myeloid leukemia and BRAF in pilocytic astrocytoma (Jones et al., 2008; Nakao et al., 1996) . Unbiased analysis identified a region $624 kb upstream of AR as the most frequent site of structural variation in mCRPC (Table S2) . AR amplification occurred in 70% of cases and was associated with significantly elevated AR mRNA expression (p = 9 3 10 À8 , Figures 2A, top, and 2B). Our result is consistent with earlier findings that AR amplification is rare in primary prostate cancer (Abeshouse et al., 2015) but common in mCRPC and is a major mechanism of resistance to androgen deprivation therapy (Visakorpi et al., 1995) . The region of peak amplification upstream of AR at 66.94 Mb was amplified in 81% of cases, 11% more frequently than AR itself ( Figure 2A , middle). Tumors frequently amplified both AR and the upstream peak (68 cases), but in 13 cases the upstream peak alone was amplified ( Figure 2B ). DNA copy gain at the upstream peak in cases that lacked AR amplification was significantly associated with elevated AR expression (p = 0.003, Figure 2B ), indicating that amplification of the upstream peak was independently associated with AR expression levels. Cases with amplification of both the upstream peak and AR had significantly higher expression than cases where only the upstream peak was amplified (p = 0.01, Figure 2B ), consistent with additive effects. Tandem duplications at the upstream peak corresponding to copy number gain break points were observed in 36% of all cases and in 44% of the 81 cases bearing copy gain at this region. Focal tandem duplication of the upstream peak region was almost exclusive to patients lacking or with low AR amplification (p < 0.0007, hypergeometric test, Figure 2C ), consistent with tandem duplication at the peak being a sufficient alternative to AR amplification. The presence of amplification at this peak was not associated with previous treatment with the secondline hormone therapies abiraterone or enzalutamide (Table S4) . We assessed the frequency of H3K27ac occupancy within the upstream peak, as H2K27ac enrichment is associated with potential enhancer activity (Heintzman et al., 2009) . Previously published data from 19 primary prostate tumors revealed that the minimally targeted region at the upstream peak was enriched for H3K27ac histone modifications (Kron et al., 2017) (Figure 2A , middle and bottom). Collectively, these data support the detection of an enhancer, amplified in 81% of castration-resistant metastatic patients, that can act independently of AR locus amplification to increase expression of AR in response to firstline ADT.
Intergenic regions near MYC at 8q24 and FOXA1 at 14q13.3 were also frequent targets of SVs (Table S2) . We observed distinct tandem duplication peaks 700 and 300 kb. upstream of MYC, with duplication frequencies of 25% and 23%, respectively ( Figure 2D , top, middle). The farther region included three long non-coding RNAs: prostate cancer associated transcript -1 and -2 (PCAT-1, PCAT-2), and prostate cancer associated non-coding RNA 1 (PRNCR1). The degree of MYC copy number amplification was modestly associated with MYC mRNA expression levels (rho = 0.28, p = 0.005). Although PRNCR1 is unlikely to be implicated in mCRPC pathogenesis (Prensner et al., 2014) , PCAT-1 has been shown to upregulate cMyc protein levels post-translationally (Prensner et al., 2014b) . The nearer region included additional non-coding genes, as well as the rs6983267 and rs1447295 germline variants associated with prostate cancer risk (Amundadottir et al., 2006; Yeager et al., 2007) . Tandem duplications overlapping FOXA1 and/or the adjacent gene mirror-image polydactyl 1 (MIPOL1) were present in 14% of samples ( Figure 2E ). These events were less frequent than AR or MYC events described above, precluding nomination of a candidate local peak, but several sites in this region had H3K27ac enrichment ( Figure 2E ). Three of the 14 samples bearing tandem duplications in this region also bore FOXA1 mutations. Observations of ETV1 translocations into this region by us ( Figure 1D ) and others (Abeshouse et al., 2015; Tomlins et al., 2007) suggest that SVs at this locus play a role in prostate cancer. These observations collectively demonstrate that unbiased analysis of tandem duplications by whole-genome sequencing identifies loci that are selected for amplification near driver genes such AR, MYC, and FOXA1 in metastatic prostate cancer, and this selection potentially drives disease progression.
DNA Repair Defects Drive SVs
To explore the etiology of SVs in prostate cancer, we identified alterations associated with SV frequency. The number of SVs identified in individual tumors ranged between 103 and 923 (337 ± 166, mean ± SD, Figure 3A ). Deletion frequency was significantly higher in tumors with biallelic BRCA2 mutations (p = 4 3 10 À6 ) (Figures 3B, left, and 3C). Additionally, we observed that biallelic inactivation of CDK12 was associated with a significant increase in tandem duplications with a bimodal length distribution ( Figures 3B center, 3C , and S5) (p = 0.003). These results were consistent with results previously reported in ovarian cancer (Popova et al., 2016) . We noted that the number of inverted rearrangements and deletions observed in each sample was significantly correlated (rho = 0.54, p < 4 3 10 À10 , Figure 3D ). Tumors bearing large numbers of both deletions and inverted rearrangements had (Fraser et al., 2017; Maher and Wilson, 2012; Stephens et al., 2011; Zack et al., 2013) (Figure 3B , right). We identified chromothripsis in 23% of mCRPC (Figure 3A, 3D ; samples listed in Table S1 ), compared with 20% reported in non-indolent primary prostate tumors (Fraser et al., 2017) . Biallelic TP53 inactivation was the event most significantly associated with elevated inverted rearrangement frequency (median 57 versus 79 inversion rearrangements, p = 0.0004) and with the presence of chromothripsis (19 of the 23 cases with chromothripsis versus 28 of the 78 cases lacking chromothripsis, p = 0.0004). No locus was preferentially targeted by chromothripsis, consistent with a stochastic process. No tumor with biallelic loss of BRCA2 also exhibited chromothripsis ( Figures 3A and 3D) . As observed in a previous pancancer analysis, chromothripsis was not associated with an Table S4 .
elevated mutation frequency genomewide (p > 0.05, Figure 3E ) (Zack et al., 2013) . In contrast, BRCA2 loss had the strongest statistical association with tumor mutational burden (median 7.0 versus 4.0 mutations/Mb, p = 0.0002, Figure 3E ). Chromoplexy, a balanced interweaving of interchromosomal translocations, has been observed in prostate cancer (Baca et al., 2013) . We identified chromoplexy in 50% of samples (Table S1 ). Of the 23 samples with chromothripsis, 12 (52%) also showed chromoplexy, as expected if there were neither positive nor negative enrichment for chromothripsis in samples that had undergone chromoplexy. The presence of somatic TP53 alterations was not associated with either translocation frequency or with the presence of chromoplexy. Our analysis therefore identified biallelic inactivation of CDK12, BRCA2, and TP53 as strongly linked to three forms of SV in mCRPC, with the link between TP53 inactivation and inversion rearrangements further linked to chromothripsis.
Mutational Signatures of DNA Damage
Cells bearing homologous recombination repair defects develop genomic scars (reviewed in Lord and Ashworth, 2016) , including deletions with homology at both ends of the deleted region. These cells rely on microhomology-mediated end joining to repair double strand DNA breaks, also known as alternative nonhomologous end-joining (Davies et al., 2017; Nik-Zainal et al., 2012 Tutt et al., 2001) . Tumors bearing biallelic loss of BRCA2 had elevated levels of deletions with flanking microhomology ( Figure 4A ). Tumors with biallelic inactivation of CDK12 or ATM, or with monoallelic alterations in BRCA1 or BRCA2, lacked this phenotype, confirming previously published observations (Polak et al., 2017) . We fitted published mutation signature profiles to somatic single nucleotide variations and performed de novo mutational profile signature analysis using non-negative matrix factorization (Alexandrov et al., 2013) . A solution including eight de novo signatures provided the optimal balance between variance explained and parsimonious modeling. Signature de novo 8 was strongly associated with samples bearing biallelic BRCA2 inactivation ( Figures 4A and  S6A ) and closely resembled COSMIC signatures 3 and 8 ( Figures  4A and S6B ), previously associated with defects in homologous recombination DNA repair (HRD) (Alexandrov et al., 2013; NikZainal et al., 2016) . COSMIC 3 signature fit was significantly elevated in samples bearing biallelic loss of BRCA2, consistent with previous reports in breast, ovarian, and prostate cancer (p = 4 3 10 À7 , Figures 4A and 4B ).
A sample with heterozygous mutation of both BRCA1 and BRCA2 lacked an elevated microhomology deletion frequency, but nevertheless showed strong de novo 8 and COSMIC 3 signature scores. In all, 6% of cases harbored compound BRCA1/2 heterozygosity, either by single copy DNA loss (n = 5) or somatic mutation (n = 1). These samples had significantly elevated muta- (Figure 4C ), but the difference in signature fit was not statistically significant. The other robust de novo signatures identified in this cohort recapitulated known signatures (Alexandrov et al., 2013) . These included de novo 1, likely identical to COSMIC signature 1 associated with spontaneous deamination of 5-methylcytosine associated with age at tumor diagnosis , and de novo 5, present in a hypermutated sample with deep deletion of mutS homolog 2 (MSH2) and MSH6, mismatch repair genes 300 kb apart on chromosome 2. This signature bore the strongest similarity to COSMIC 6 (associated with defective MMR) and COSMIC 9 (activation-induced deaminase activity during hypermutation). These data confirmed that DNA repair defects in mismatch repair and homologous recombination can produce genomic scars in metastatic prostate cancer and showed that BRCA1/2 compound heterozygosity produces a mutational phenotype distinct from that of biallelic BRCA2 inactivation.
A Landscape of Mutations and Structural Alterations
Somatic alterations and structural variants for 44 key prostate cancer genes are shown in Figure 5 , and listed in Table S5 . The somatic mutation frequencies were consistent with previous reports in mCRPC (Armenia et al., 2018; Robinson et al., 2015) . In total, 85% of mCRPC samples carried either pathogenic activating AR mutations, amplifications of AR, or putative AR enhancer region amplifications, an increase over the 63% of cases identified as carrying AR alterations in a benchmark exome study of comparable size . ETS family genes were activated by fusions in 59% of cases. We observed MAPK driver mutations in HRAS (p.Q61K, 2%) and BRAF (p.G469A, 1%). Putative dominant negative SPOP mutations were present in 5% of cases (Barbieri et al., 2012; Blattner et al., 2017) . ETS gene family activations were mutually exclusive with activating alterations in the RAS/MAPK pathway members (p = 0.01, Fisher's exact test) and with inactivation of SPOP and CHD1 (Barbieri et al., 2012; Burkhardt et al., 2013; Huang et al., 2012) . A single IDH1 mutation at the previously reported p.R132C hotspot was observed (Abeshouse et al., 2015) . Additionally, mutually exclusive alterations affecting genes that modulate the AR pathway (FOXA1, NCOR1, NCOR2, and ASXL2) were present in 29% of cases. Alterations in WNT pathway members CTNNB1, APC, and ZNRF3 that were predicted to activate WNT signaling were mutually exclusive in all but one of the 17% of cases where they were present. Previously unreported inactivating events targeting HDAC4 were present in 6% of cases. No somatic alteration was significantly associated with tissue biopsy site after accounting for multiple testing correction. We searched for recurrent point mutations affecting the promoter, enhancer, and UTR regions of 574 known cancer driver genes (Table S5 ). This analysis identified 101 mutations of unknown significance; no variant was significantly associated with expression or structural variation phenotypes.
We next assessed the frequency of mutations in genes responsible for DNA damage repair. Inactivating germline alterations were present in the DNA repair genes (BRCA2 and ATM) in 4% of samples, a slightly lower frequency than the $10% frequency observed in a large study of metastatic prostate tumors (Pritchard et al., 2016) . Somatic alterations alone accounted for five of the eight cases of biallelic BRCA2 inactivation and all three tumors carrying biallelic CDK12 inactivation. Biallelic BRCA2, CDK12, and ATM inactivating mutations were mutually exclusive, and the total frequency of biallelic BRCA2, CDK12, and ATM inactivation was 15%. Two hypermutated samples were present, consistent with the reported 3% frequency of mismatch repair defects in mCRPC . One hypermutated sample bore deep deletion in mutS homolog 2 (MSH2) and MSH6, mismatch repair genes 300 kb apart on chromosome 2, an alteration predicted to abrogate mismatch repair.
DISCUSSION
In contrast to previously published large-scale analyses of primary and metastatic prostate cancer that have largely focused on the coding genome (Abeshouse et al., 2015; Armenia et al., 2018; Barbieri et al., 2012; Beltran et al., 2013; Fraser et al., 2017; Robinson et al., 2015; Taylor et al., 2010; Wedge et al., 2018) , we have performed whole-genome analysis of metastases from 101 mCRPC patients at 109x depth of coverage in tumor samples. This coverage, 2-fold deeper than previous efforts in this space (Wedge et al., 2018) and performed on a large patient cohort, has produced a unique resource for dissecting structural variation in metastatic prostate cancer samples. Our data emphasize that structural variations may inactivate tumor suppressors by disrupting the coding region of these genes Waddell et al., 2015) , whereas both fusions and alterations affecting intergenic regulatory elements appear to activate driver genes. Fusions driving proteins such as AXL or BRAF that can be targeted therapeutically may open directions for new treatments in mCRPC. We derived insight into the etiology of structural variation, associating BRCA2, CDK12, and TP53 with deletions, tandem duplications, and chromothripsis. Our novel observation that non-coding RNAs such as SCHLAP1 and RP11-356O9.1 drive oncogene expression highlights the under-explored role of non-coding genes in mCRPC and will serve as the foundation for further studies of the noncoding genome.
All of the men in this study had developed resistance following front-line treatment with androgen deprivation therapy (ADT). A key finding made possible by our integrated analysis of the whole genome and transcriptome across a large population of mCRPC patients is that amplification of a putative enhancer region 624 kb distant from AR was present in 81% of men and 85% had either amplification or pathogenic activating AR mutation. Our data support the model that amplification at the putative enhancer locus results in increased AR expression. In 13% of men, putative enhancer amplification was present without alterations in AR itself. This finding suggests that DNA copy gain affecting this locus, commonly by tandem duplication, may be a frequent mechanism by which prostate tumor cells initially develop ADT resistance (Karantanos et al., 2013) . Observations of tandem duplication at putative enhancers near AR, MYC, and FOXA1 underline the value of whole-genome analysis, even in diseases where exome analysis has been performed in large cohorts of patients. We observed chromothripsis in 23% of mCRPC patients and demonstrated that chromothripsis was significantly associated with TP53 alterations. This observation supports the proposed but unproven mechanistic association between TP53 alteration and chromothripsis (Rausch et al., 2012; reviewed in Maher and Wilson, 2012) . However, TP53 alterations cannot be the sole driver of chromothripsis, as chromothripsis is not widespread in other tumors with high rates of TP53 inactivation such as high grade serous ovarian carcinoma (Zack et al., 2013) . In our study, chromothripsis was mutually exclusive with biallelic inactivation of BRCA2, inconsistent with a model where cells lacking the ability to perform homologous recombination repair of double-strand DNA breaks would be predisposed to chromothripsis.
Our study linked biallelic inactivation of BRCA2 but not ATM or CDK12 with deletions that manifest flanking microhomology (Figure 4A) . It is not yet clear what combination of genotype and genomic data will best identify the patients who will benefit Tables S3 and S5. from PARP inhibitor therapy (Mateo et al., 2015) . The 6% of samples with compound BRCA1/BRCA2 heterozygosity lacked deletions with flanking microhomology but had significantly increased mutation rates not statistically distinguishable from biallelic BRCA2 tumors. Dissecting the functional consequences of these alterations will have implications for patient selection when considering treatment with a PARP inhibitor (Lord and Ashworth, 2016) .
Our study demonstrates the utility of whole-genome analysis across a clinically relevant metastatic tumor cohort, as our analysis led to multiple discoveries that eluded existing exome-centric genomic investigations in the advanced disease setting. We have provided the first landscape of structural variants in mCRPC, a substantial mutational class in this disease that will serve as a repository for other researchers to continue exploring their biological and clinical significance. Our data also provides the foundation for further dissection of the non-coding genome through complementary profiling efforts (e.g., epigenetics) and subsequent preclinical studies that may have translational impact in prostate cancer patients.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
Mutation signature analysis
To perform per-sample mutation counting, all somatic mutations that were not excluded by quality filtering steps were counted. For mutation signature analysis this list was filtered using snpSift version 4.3g, including all alterations designated with the call ''SNP'' (Cingolani et al., 2012a) . Evaluation of COSMIC mutation signatures was performed using the deconstructSigs package (Rosenthal et al., 2016) , using the BSgenome.Hsapiens.UCSC.hg38 reference, the signatures.cosmic comparison set, a signature.cutoff value of 0.06, and a tri.counts.method parameter of ''default.'' De novo mutation signatures were derived using non-negative matrix factorization implemented in the SomaticSignatures R package (Gehring et al., 2015) .
Evaluation of deletions with flanking microhomology
Deletions bearing microhomology were identified by a script counting deletions with two or more nucleotides of identical sequence between either 1) the 5 0 end of the deleted region (determined from the HG38 genome reference) and the 3 0 end following the deleted region or 2) the 3 0 end of the deleted region and the 5 0 end immediately preceding the deletion.
Evaluation of chromothripsis and chromoplexy
Chromothripsis was evaluated by counting the number of insertions, deletions, and copy number alterations within a moving 20 Mb. window positioned at 10 Kb. intervals along the entire genome, excluding telomeres and centromeres. Windows bearing at least 15 inversion rearrangements, 15 alternating copy number switches, and 10 deletions were called positive for chromothripsis. Chromoplexy was evaluated by applying the ChainFinder application version 1.0.1 (Baca et al., 2013) obtained from http://archive. broadinstitute.org/cancer/cga/chainfinder, using a deletion threshold of À0.278 and a significance threshold of 0.05. The presence of chromoplexy was defined by the presence of a chromoplexy chain connecting at least three chromosomes.
Noncoding mutation analysis
Recurrent promoter and untranslated region (UTR) point mutations were nominated by identifying mutations with variant allele frequency of at least 10% that were present in gene untranslated regions, enhancers, or promoters. UTR and promoter annotation were performed using ANNOVAR v2018Apr16 (Wang et al., 2010) . Promoter regions were defined as 1 Kb upstream of the transcription start site. Enhancer regions were nominated by intersecting regions predicted by GeneHancer (Fishilevich et al., 2017) with regions enriched for H3K27ac histone modification identified by CHIPseq in (Kron et al., 2017) . A peak in any of 19 samples in that dataset was considered sufficient for inclusion in this analysis. Analysis of recurrent mutations in noncoding regions was restricted to regulatory regions predicted to affect any of the 574 genes listed in Tier 1 of the COSMIC Cancer Gene Census v85, obtained from https://cancer.sanger.ac.uk/cosmic/census (Futreal et al., 2004) .
Data visualization and reporting
Circos plots were generated using the RCircos R package (Zhang et al., 2013) .
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Analysis All statistical analysis was performed using R (v3.3.3) (R Core Team, 2018) . Between-group comparisons of continuous variables were performed with the Wilcoxon rank sum test. Contingency table tests were performed with Fisher's exact test. Correlation was assessed with Spearman's correlation. All tests were two-sided.
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Sequencing Data
The accession number for the raw sequencing data reported in this paper is dbGAP: phs001648.v1.p1. Table S1 (A) Mean copy number. Baseline copy number for chromosomes X and Y is 1 copy.
(B) Mean genome-wide ploidy estimates. Estimated ploidy values for each sample are listed in Table S1 . (C) RNA sequence of an ACPP-AXL fusion observed independently in a patient seen at the Vancouver Prostate Center; RNA generated from fresh frozen tumor tissue (radical prostatectomy) with high risk primary prostate cancer and methodology described in Wyatt et al. (2014) . 
